Image Credit: Scientific Frontline / stock image
Scientific Frontline: Extended "At a Glance" Summary: Rituximab and Inflammatory Bowel Disease Risk
The Core Concept: Rituximab, an anti-CD20 therapy frequently used to treat multiple sclerosis, is associated with a significantly increased, though absolutely low, risk of developing inflammatory bowel disease compared to other highly effective multiple sclerosis treatments.
Key Distinction/Mechanism: While highly effective at preventing multiple sclerosis relapses by targeting CD20-positive B cells, rituximab is linked to an approximately tenfold higher relative risk of inflammatory bowel disease, particularly Crohn's disease, when compared to alternative therapies like natalizumab, dimethyl fumarate, and fingolimod.
Major Frameworks/Components:
- The study analyzed data from Swedish registers covering nearly 14,000 treatment episodes in patients with relapsing-remitting multiple sclerosis.
- Researchers compared rituximab against three other therapies: natalizumab, dimethyl fumarate, and fingolimod.
- The absolute risk remains low, with fewer than 2% of patients in any treatment group developing inflammatory bowel disease within 10 years of starting treatment.
- The risk increase translates to roughly one additional case of inflammatory bowel disease for every 131 patients treated with rituximab for five years instead of an alternative treatment.
Branch of Science: Neurology, Gastroenterology, Pharmacology.
Future Application: The findings will guide neurologists in personalizing multiple sclerosis treatment plans, necessitating a careful evaluation of the benefits of anti-CD20 drugs against the potential adverse effect of inflammatory bowel disease for each individual patient.
Why It Matters: Although anti-CD20 therapies are among the most effective disease-modifying treatments for multiple sclerosis, this research provides the first quantitative evidence from a large population-based study confirming clinical reports of inflammatory bowel disease, thereby informing patient risk-benefit assessments.
People with multiple sclerosis (MS) who are treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn’s disease, although the absolute risk remains low. This is according to the first large population-based study in the field, led by researchers at Karolinska Institutet and published in JAMA Neurology.
Rituximab belongs to a group of drugs known as anti-CD20 therapies and is currently the most used disease-modifying treatment for MS in Sweden. As the use of anti-CD20 therapies has increased, cases of inflammatory bowel disease have been reported among patients receiving these treatments, raising concerns among neurologists. Until now, however, evidence from large studies has been lacking. The new study is the first population-based study to systematically investigate the association.
The researchers analyzed nearly 14,000 treatment episodes among people with relapsing-remitting MS, using data from Swedish registries. They compared rituximab with three other highly effective MS treatments: natalizumab, dimethyl fumarate, and fingolimod.
Inflammatory bowel disease was more common among people treated with rituximab than among those receiving any of the other three treatments, even after differences in follow-up time were taken into account. After adjusting for other differences between the groups, the researchers found that the risk was around ten times higher with rituximab than with the other MS treatments.
Few patients developed the disease
Despite the increased relative risk, the absolute risk remained low. Fewer than two percent of patients in any of the treatment groups developed inflammatory bowel disease within ten years of starting treatment. The increase in risk corresponded to approximately one additional case for every 131 patients treated with rituximab for five years rather than with one of the other treatments. Most of the cases were Crohn’s disease.
“This is the first large study to quantify the risk of inflammatory bowel disease associated with anti-CD20 treatment for MS. The results show that this is a potential adverse effect that should be considered when choosing an MS treatment. At the same time, the increased risk needs to be weighed against the benefits for the individual patient. Anti-CD20 drugs are among the most effective treatments for preventing MS relapses,” says Peter Alping, researcher at the Department of Medicine, Solna, and last author of the study.
Published in journal: JAMA Neurology
Title: Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis
Authors: Sandra Kallin, Anders Svenningsson, Ola Olén, Charlotte Hedin, Jan Lycke, and Peter Alping
Source/Credit: Karolinska Institutet | Anna Björklund
Edited by: Scientific Frontline
Reference Number: ns102226_04